Sigvotatug vedotin vs docetaxel in pretreated nonsquamous NSCLC: Pfizer said in June the phase 3 missed its OS endpoint. Our faculty member Solange Peters (@peters_solange) presents the data at #ESMO26, LBA68, Sun 25 Oct, 11:13, Hall 6. Calendar file: https://t.co/T7PqGHFhac Is it on your list? @myESMO